IMPACT OF ANTICOAGULANT THERAPY ON HEMOSTATIC AND INFLAMMATORY MARKERS IN PATIENTS WITH IMMUNE-MEDIATED MICROVASCULAR THROMBOSIS
Authors/Creators
- 1. Scientific Supervisor: Doctor of Science, Associate Professor Tashkent State Medical University, Tashkent, Uzbekistan
- 2. Scientific Consultant: Doctor of Medical Sciences Tashkent State Medical University, Tashkent, Uzbekistan
- 3. Laboratory Work of a Master's Student Tashkent State Medical University, Tashkent, Uzbekistan
Description
Immune-mediated microvascular thrombosis (IMMT) is a complex disorder driven by immune dysregulation, leading to microvascular occlusion and necessitating anticoagulant therapy. This study evaluates the impact of anticoagulant therapy on hemostatic parameters (D-dimer, fibrinogen, prothrombin time [PT], activated partial thromboplastin time [APTT]) and inflammatory markers (C-reactive protein [CRP], interleukin-6 [IL-6]) in 45 patients with IMMT. Patients were followed for 12 months, receiving either warfarin or direct oral anticoagulants (DOACs). D-dimer levels decreased significantly (1.5 µg/mL to 0.6 µg/mL, p<0.01), with DOACs showing greater reduction (p=0.02). Fibrinogen remained elevated in 60% of patients (mean 4.3 ± 0.9 g/L), correlating with CRP (r=0.65, p<0.01). IL-6 levels declined from 12.5 pg/mL to 5.8 pg/mL (p<0.05), reflecting reduced inflammation. Thrombotic recurrence occurred in 18% of patients, associated with persistent fibrinogen elevation (OR 2.9, 95% CI 1.1–7.6, p=0.03). These findings highlight the role of hemostatic and inflammatory markers in monitoring therapy efficacy and predicting outcomes in IMMT, supporting personalized treatment approaches.
Files
137-142.pdf
Additional details
References
- 1. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019-1027. doi:10.1002/art.10187
- 2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x
- 3. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med. 2017;377(12):1177-1187. doi:10.1056/NEJMra1700365
- 4. Lippi G, Favaloro EJ. D-dimer measurement and laboratory feedback. J Thromb Haemost. 2017;15(7):1453-1456. doi:10.1111/jth.13706
- 5. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk. J Am Coll Cardiol. 2007;49(21):2129-2138. doi:10.1016/j.jacc.2007.02.054